RARITAN, N.J., Aug. 1 /PRNewswire/ -- Veridex, LLC announced today it has completed its previously announced acquisition of substantially all of the assets of Immunicon Corporation and its wholly-owned subsidiaries.
The assets acquired include intellectual property, product inventory and clinical data as well as all technologies related to the CellSearch(TM) System, the first diagnostic test to automate the detection and enumeration of circulating tumor cells (CTCs), cancer cells that detach from solid tumors and enter the blood stream. The CellSearch(TM) System is currently cleared for the prognosis and monitoring of patients with metastatic breast, metastatic colorectal and metastatic prostate cancer. As part of the agreement, Veridex also received all technologies related to Repeat-Free(TM) (RF) Poseidon(TM) Fluorescent In-Situ Hybridization (FISH) Probes, which are the latest advance in FISH DNA probes.
"This asset purchase ensures the role of CellSearch(TM) in the future of Veridex," said Ken Berlin, General Manager, Veridex, LLC. "It underscores our continued commitment to the medical community and to cancer patients who may benefit from technologies like the CellSearch(TM) System."
Veridex and Immunicon have partnered since 2000 to develop and commercialize novel cancer diagnostic platforms and products.
Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value in vitro diagnostic oncology products. Veridex's products may significantly benefit patients through earlier disease detection and may enable personalized strategies to help improve patient management and outcomes. For more information, please visit www.veridex.com.
CONTACT: Media, Stephanie Fagan, +1-201-572-9581, or Investor, Louise
Mehrotra, +1-732-524-6491, or Stan Panasewicz, +1-732-524-2524, all for
Web site: http://www.veridex.com/